Financial Performance - The company achieved operating revenue of CNY 92,427,565.79, an increase of 41.55% compared to the same period last year[19]. - Net profit attributable to shareholders reached CNY 9,137,559.30, reflecting an 86.83% increase year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 11,931,445.63, a significant increase of 369.91% compared to the previous year[19]. - Basic earnings per share rose to CNY 0.0204, up 87.16% from the previous year[19]. - The total profit for the current period is CNY 8,576,423.18, compared to CNY 3,719,946.73 in the previous period, showing an increase of 130.5%[107]. - The total comprehensive income for the current period is CNY 9,137,559.30, compared to CNY 3,913,071.11 in the previous period, indicating an increase of 133.0%[107]. - The company reported a net profit of ¥9,137,559, contributing positively to the equity attributable to shareholders[119]. Cash Flow - The net cash flow from operating activities was CNY 75,883,764.67, a remarkable increase of 4,637.77% year-on-year[19]. - The cash flow from operating activities for the current period is CNY 75,883,764.67, a significant increase from CNY 1,601,677.78 in the previous period[113]. - The net cash flow from operating activities was ¥79,566,663.45, a significant improvement compared to a negative cash flow of ¥403,112.60 in the previous period, indicating a positive operational performance[117]. - Total cash inflow from operating activities reached ¥186,257,272.20, up from ¥84,044,139.61, reflecting a year-over-year increase of approximately 121%[117]. - The ending balance of cash and cash equivalents was ¥9,894,023.81, a decrease from ¥20,691,063.97 in the previous period, reflecting a decline of approximately 52%[118]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,156,680,176.10, an increase of 4.49% from the end of the previous year[19]. - Total liabilities were reported at ¥415,348,777.15, an increase from ¥363,896,633.62, representing a rise of 14.1%[104]. - Current assets totaled ¥510,747,532.34, an increase of 9.2% from ¥467,380,552.65 at the beginning of the period[103]. - Non-current assets increased to ¥649,472,244.73, up from ¥612,252,316.69, reflecting a growth of 6.1%[104]. - The total owner's equity at the end of the current period is 724,878,600 yuan, showing a change from the previous period's 720,524,000 yuan[128]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,040[84]. - The total number of shares before the change was 449,016,276, with no changes in the number of shares during the reporting period[83]. - The largest shareholder, Changchun Yungxin Investment Co., Ltd., transferred 80,000,000 shares to Beijing Ivy League Investment Management Co., Ltd., representing 17.82% of the total share capital[132]. - Changchun Yungxin Investment Co., Ltd. retains 21,436,034 shares, accounting for 4.77% of the total share capital, making it the second-largest shareholder[132]. Operational Strategy - The company plans to enhance internal management and control costs while expanding external market development[27]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[106]. - The company has committed to injecting at least 500 million RMB into the business for GMP certification, industry mergers and acquisitions, new product development, and marketing channel construction within 18 months of completing the equity transfer registration procedures[74]. Governance and Compliance - The company has maintained a compliant governance structure in accordance with relevant laws and regulations[52]. - The company has not experienced any major litigation or arbitration matters during the reporting period[53]. - The company has not engaged in any significant related party transactions during the reporting period[60]. - The company will ensure compliance with relevant regulations and company management systems while exercising shareholder rights[75]. Financial Reporting - The company prepares financial statements based on the going concern principle and adheres to the accounting standards issued by the Ministry of Finance[133]. - The financial statements reflect the company's financial position, operating results, changes in shareholders' equity, and cash flows accurately and completely[134]. - The company’s financial report for the half-year was not audited[97]. - The company has not audited its semi-annual financial report[76]. Investment and Assets Management - The company has not made any asset acquisitions or sales during the reporting period[56][57]. - The company has not reported any new product launches or technological advancements in the current period[126]. - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, with specific criteria for available-for-sale financial assets and held-to-maturity investments[155].

Financial Performance - The company's operating revenue for 2013 was CNY 147,781,836.93, representing a 15.77% increase compared to CNY 127,647,611.13 in 2012[21]. - The net profit attributable to shareholders for 2013 was CNY 4,092,133.24, a 6.11% increase from CNY 3,856,634.96 in 2012[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 57.26% to CNY 2,294,378.70 from CNY 5,368,189.38 in 2012[21]. - The net cash flow from operating activities significantly improved to CNY 102,962,801.99, a 1,685.45% increase from a negative CNY 6,494,214.11 in 2012[21]. - Total assets at the end of 2013 reached CNY 1,106,992,392.01, marking a 23.7% increase from CNY 894,890,628.51 at the end of 2012[21]. - The net assets attributable to shareholders decreased slightly by 0.73% to CNY 615,080,936.63 from CNY 619,604,800.37 in 2012[21]. - The basic earnings per share remained stable at CNY 0.01, unchanged from 2012[21]. - The diluted earnings per share also remained at CNY 0.01, consistent with the previous year[21]. - The weighted average return on net assets increased to 0.69% from 0.63% in 2012[21]. Revenue and Expenses - Total revenue for the period was ¥147,781,836.93, reflecting a 15.77% growth year-over-year[32]. - The total cost of sales increased by 23.58% to ¥173,170,718.85, indicating rising operational expenses[33]. - Research and development expenses amounted to ¥6,422,053.47, which is 4.35% of total revenue[40]. - Sales expenses rose by 42.97% to ¥48,437,795.24, driven by increased market promotion efforts[39]. Cash Flow and Investments - Operating cash inflow increased by 75.06% to ¥299,337,250.33, while operating cash outflow rose by 10.64%[42]. - Investment cash inflow increased year-on-year mainly due to dividends received from Changchun Rural Commercial Bank and cash from the sale of remaining equity in Shuanglong Chemical[43]. - Investment cash outflow increased year-on-year due to equipment and construction costs for new facilities and an investment of 67.65 million yuan in Changchun Rural Commercial Bank[43]. - Financing cash inflow increased year-on-year due to a 30 million yuan short-term loan from the bank, a 60 million yuan loan from major shareholder Beijing Changqing Teng Lianchuang Investment Management Co., Ltd., and 14.4 million yuan in government subsidies for new project construction[43]. Market and Product Performance - Revenue from the pharmaceutical industry reached 147.65 million yuan, with a year-on-year increase of 15.97% and a gross margin of 51.53%[44]. - The company reported a significant increase in revenue for the product "Xiao Ai Ping Pian" by 107.83% year-on-year, with a gross margin of 69.26%[44]. Shareholder and Governance Matters - The company plans not to distribute cash dividends or issue bonus shares for the year[5]. - The company has not distributed any cash dividends in the past three years, with all profits used to offset previous losses[86]. - In 2013, the total cash dividend amount was 0.00, representing 0% of the net profit attributable to shareholders[87]. - The company has established a governance structure to protect the rights of all shareholders and creditors[88]. - The company has revised its profit distribution policy to ensure compliance and transparency, providing opportunities for minority shareholders to express their opinions[85]. Risks and Future Strategies - The company faces risks from fluctuating raw material costs and potential impacts from ongoing healthcare reforms, which may pressure profit margins[79]. - The company aims to enhance its market development and strengthen core products to achieve sustainable and rapid growth in the pharmaceutical industry[79]. - The company’s future development strategy includes a focus on innovation and expanding its product offerings in response to market competition[79]. Internal Control and Compliance - The company has established a comprehensive internal control system, which effectively executed and improved operational management and risk prevention capabilities[184]. - The audit report issued by Zhongzhun Accounting Firm confirmed that the company maintained effective internal control over financial reporting in all material respects as of December 31, 2013[188]. - The company has not experienced any significant accounting errors or omissions during the reporting period, ensuring the accuracy of financial disclosures[189]. Employee and Management Structure - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 8,095,000 CNY, with an additional 1,200,000 CNY from shareholder units, totaling 9,295,000 CNY[153]. - The company employed a total of 899 staff members, with 440 in production, 164 in sales, 73 in technology, 30 in finance, and 192 in administration[157]. - The management team saw changes with the appointment of Wang Fuli as General Manager on May 21, 2013, following the departure of Wu Chengyu[155]. Shareholder Transactions - A total of 8,000,000 shares were transferred from Tonghua City Yongxin Investment Co., Ltd. to Beijing Changqing Teng Investment Management Co., Ltd. after approval from the State-owned Assets Supervision and Administration Commission[131]. - The company has initiated a non-public stock issuance, which has been approved by the board of directors, supervisory board, and shareholders' meeting, with materials being prepared for submission to the China Securities Regulatory Commission[129].